William Surbeck, MD
Rheumatology · Tulsa, OKNPI 1154382711
Payments from drug & device makers
Across 881 payments — averaging $92.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$34K
- Eli Lilly$33K
- Johnson & Johnson$4K
- Amgen$3K
- UCB, Inc.$2K
- GSK$809
- plus $4K from 19 others
Across 1 payment — averaging $539.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$539
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 192 | $33,625 |
| Eli Lilly | 3 | $33,479 |
| Johnson & Johnson | 85 | $4,324 |
| Amgen(2 entities) | 195 | $3,446 |
| UCB, Inc. | 81 | $1,613 |
| GSK | 49 | $809 |
| Genentech USA, Inc. | 47 | $705 |
| Pfizer | 48 | $698 |
| Novartis | 41 | $651 |
| Lilly USA, LLC | 30 | $535 |
| AstraZeneca | 26 | $489 |
| E.r. Squibb & Sons, L.L.C. | 34 | $429 |
| Aurinia Pharma U.S., Inc. | 17 | $317 |
| Radius Health, Inc. | 5 | $96 |
| Bristol Myers Squibb | 5 | $85 |
| Fresenius Kabi USA, LLC | 4 | $81 |
| Sandoz | 4 | $78 |
| Sobi, Inc | 3 | $62 |
| Sanofi | 3 | $60 |
| Boehringer Ingelheim | 4 | $56 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Celltrion USA Inc. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
How this compares
$81,745 in reported general payments places this provider in the 80th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Tulsa
- Basmah JalilTulsa$5.2M
- James McKayTulsa$945K
- Debbie FoleyTulsa$488K
- Ellen ZanetakisTulsa$80K
- Alan MartinTulsa$22K
- Mary Hinojos MamutTulsa$21K
- Manuel CalvinTulsa$19K
- Michael MalloyTulsa$13K
- Priyatha GarlapatiTulsa$8K
- Lindsay CunninghamTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.